← Eichor
Study identifier: NCT03424850 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy

Condition: Prostate Cancer · Prostate Neoplasm  ·  Sponsor: Washington University School of Medicine

PhasePhase 1/Phase 2
Planned participants36
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this research study is to learn more about the outcomes and early and late side effects of treating early stage prostate cancer with high dose rate brachytherapy.

This description comes directly from the study's public registry record.

Talk to the study team

Hiram A Gay, M.D.  ·  314-362-8516  ·  hiramgay@wustl.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Washington University School of MedicineSt Louis, Missouri, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03424850